Sensitive and easy screening for circulating tumor cells by flow cytometry.
Adult
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ blood
Cell Line, Tumor
Cell Separation
/ methods
Cell Size
Colonic Neoplasms
/ blood
Female
Flow Cytometry
/ methods
Follow-Up Studies
Humans
Liquid Biopsy
/ methods
Male
Middle Aged
Neoplastic Cells, Circulating
/ metabolism
Prognosis
Proof of Concept Study
Prospective Studies
Sensitivity and Specificity
Survival Analysis
Breast cancer
Cancer
Colorectal cancer
Oncology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
13 06 2019
13 06 2019
Historique:
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Circulating Tumor Cells (CTCs) represent an easy, repeatable and representative access to information regarding solid tumors. However, their detection remains difficult because of their paucity, their short half-life, and the lack of reliable surface biomarkers. Flow cytometry (FC) is a fast, sensitive and affordable technique, ideal for rare cells detection. Adapted to CTCs detection (i.e. extremely rare cells), most FC-based techniques require a time-consuming pre-enrichment step, followed by a 2-hours staining procedure, impeding on the efficiency of CTCs detection. We overcame these caveats and reduced the procedure to less than one hour, with minimal manipulation. First, cells were simultaneously fixed, permeabilized, then stained. Second, using low-speed FC acquisition conditions and two discriminators (cell size and pan-cytokeratin expression), we suppressed the pre-enrichment step. Applied to blood from donors with or without known malignant diseases, this protocol ensures a high recovery of the cells of interest independently of their epithelial-mesenchymal plasticity and can predict which samples are derived from cancer donors. This proof-of-concept study lays the bases of a sensitive tool to detect CTCs from a small amount of blood upstream of in-depth analyses.
Identifiants
pubmed: 31194699
pii: 128180
doi: 10.1172/jci.insight.128180
pmc: PMC6675556
doi:
pii:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Cancer. 2000 Jan 20;89(1):8-13
pubmed: 10719724
J Immunol Methods. 2000 May 26;239(1-2):13-23
pubmed: 10821943
Clin Biochem. 2004 Jul;37(7):529-40
pubmed: 15234234
Oncogene. 2006 Apr 6;25(15):2273-84
pubmed: 16288205
Eur J Cancer. 2006 Nov;42(16):2671-4
pubmed: 16978860
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Cytometry A. 2009 Apr;75(4):344-55
pubmed: 18855920
Cell Oncol. 2008;30(6):463-71
pubmed: 18936523
Pharmacogenomics. 2009 Jan;10(1):51-7
pubmed: 19102715
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Breast Cancer Res Treat. 2009 Dec;118(3):523-30
pubmed: 19597704
J Oncol. 2009;2009:804108
pubmed: 19636422
J Oncol. 2010;2010:426218
pubmed: 20049168
Sci Transl Med. 2010 Mar 31;2(25):25ra23
pubmed: 20424012
Cytometry A. 2011 Feb;79(2):107-17
pubmed: 21246706
Cell Death Dis. 2011 Jul 07;2:e179
pubmed: 21734725
J Cell Biol. 2011 Oct 3;195(1):19-26
pubmed: 21949415
Clin Chem. 2012 May;58(5):936-40
pubmed: 22205690
Cytometry A. 2012 Jun;81(6):489-95
pubmed: 22438318
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e685-90
pubmed: 22583603
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Methods. 2013 Dec 1;64(2):114-8
pubmed: 23896286
Science. 2013 Sep 13;341(6151):1186-8
pubmed: 24031008
Lab Chip. 2014 Jan 7;14(1):147-56
pubmed: 24202699
Cytometry A. 2014 Mar;85(3):206-13
pubmed: 24327318
Cancer Discov. 2014 Jun;4(6):650-61
pubmed: 24801577
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
PLoS One. 2014 Oct 31;9(10):e111597
pubmed: 25360587
Cancer Res. 2015 Jul 1;75(13):2749-59
pubmed: 25948589
J Am Coll Surg. 2015 Sep;221(3):699-707
pubmed: 26209458
Oncology. 2015;89(6):360-4
pubmed: 26413717
Oncotarget. 2015 Dec 29;6(42):44623-34
pubmed: 26556851
Oncotarget. 2016 Apr 26;7(17):24677-87
pubmed: 27013581
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Clin Chem. 2016 Nov;62(11):1504-1515
pubmed: 27630154
Nat Med. 2017 Jan;23(1):114-119
pubmed: 27869802
Anticancer Res. 2017 Jan;37(1):169-173
pubmed: 28011487
Cell. 2017 Feb 9;168(4):742-742.e1
pubmed: 28187292
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Clin Cancer Res. 2017 Sep 1;23(17):5112-5122
pubmed: 28615267
Sci Rep. 2017 Jul 10;7(1):4971
pubmed: 28694485
Cancer Res. 2017 Oct 15;77(20):5687-5698
pubmed: 28819021
Genes Dev. 2017 Sep 15;31(18):1827-1840
pubmed: 29051388
Cancer Med. 2017 Dec;6(12):2850-2857
pubmed: 29105339
Oncotarget. 2017 Aug 4;8(63):107223-107236
pubmed: 29291024